Massachusetts Institute of Technology

Novartis Ag

Children's Medical Center Corporation

The University of Chicago

Lonza Sales Ag

Delai Chen

Robert Samuel Langer

Daniel Griffith Anderson

Kevin Thomas Love

Arturo Jose Vegas

Andrew John Geall

Minglin Ma

Frederic Zecri

Luis Brito

Yizhou Dong

Omid Veiseh

Akinleye C Alabi

Joshua C Doloff

Thomas Zabawa

Gabriel Grant Gamber

Christian J Kastrup

Yi Heng Chen

Yunlong Zhang

Rustem F Ismagilov

Wenbin Du

Jason E Kreutz

Feng Shen

Kevin Paul Flood Nichols

Douglas E Williams

Joseph R Dorkin

Robert S Langer, Jr

Liang Li

Robert S Langer

Joshua Charles Doloff

Damian J Houde

Hao Yin

Weishan Liu

Young Jun Choi

Ahmed A Eltoukhy

Jason Eugene Kreutz

Akinleye Alabi

Yi Chen

Described herein are novel rapid and reliable methods of detection of extracellular vesicles and quantifying extracellular vesicle concentrations and absolute number from various sources, including raw cell harvest. The methods described herein comprise detection of light scattering of extracellular vesicles in biological samples. Extracellular vesicles analyzed by the methods of this application have a stereotypical elution profile distinct from known contaminants. The methods described herein are a significant improvement over the state of the art and fulfills an unmet need in the field of extracellular vesicle manufacturing and quality control.

Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering

Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as 'APPLs'. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R', R, R, R, R, R, R, Z, W, Y, and Z are as defined herein.

Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof

Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates

This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R-R, L, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Lipids and lipid compositions for the delivery of active agents

This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R-R, n, p, Land Lare defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

A device is described having a first surface having a plurality of first areas and a second surface having a plurality of second areas. The first surface and the second surface are opposed to one another and can move relative to each other from at least a first position where none of the plurality of first areas, having a first substance, are exposed to plurality of second areas, having a second substance, to a second position. When in the second position, the plurality of first and second areas, and therefore the first and second substances, are exposed to one another. The device may further include a series of ducts in communication with a plurality of first second areas to allow for a substance to be disposed in, or upon, the plurality of second areas when in the first position.

Slip chip device and methods

This invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R-R, n, p, Land Lare defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues. 

This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R-R, n and p are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues. 

Growing community of inventors

Cambridge, MA, United States of America

Delai Chen